The global high pressure contrast media injectors market size is expected to reach USD 423.8 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.7% from 2024 to 2030. The market is primarily driven by the factors such as the increasing number of target diseases, such as cardiovascular diseases, neurovascular, and cancer also the rising demand for minimally invasive surgical procedures is a major factor expected to boost the market during the forecast period.
Technological advances have contributed to the expansion of the market. For instance, several advancements in contrast media injector technology have been made to reduce contrast media waste and automate data collection about the dose a patient receives. Automated injector systems, for example, precisely gather the amount of contrast media used, and companies have begun to offer personalized doses for patients based on data from EMR or PACS. Syringeless injectors are one such advancement in lowering contrast media waste.
The increasing prevalence of cardiovascular diseases, cancer, orthopedic cases, gastrointestinal diseases, and vascular diseases globally is anticipated to boost the demand for contrast injectors, as they are the most common clinical applications for contrast-enhanced imaging systems. As a result of major companies' continued R&D spending and efforts to launch their products at a low cost, Asia Pacific is predicted to have the fastest CAGR from 2024 to 2030. In addition, the medical tourism business in the region is rapidly developing. The regional market will be boosted even higher by expanding healthcare infrastructure and increased per capita spending.
Request a free sample copy or view report summary: High Pressure Contrast Media Injectors Market Report
The consumable segment was the largest revenue-generating segment in 2023 owing to its benefits such as user-friendly, high efficiency, and minimal contrast media wastage
The single head injectors segment accounted for the largest revenue share in 2023, whereas the dual-head injector segment is expected to grow at a significant rate during the forecast period
The interventional cardiology segment held the largest revenue share in 2023 because of the rising prevalence of cardiac diseases, such as coronary artery disease, heart valve disease, and peripheral vascular disease
In 2023, North America dominated the market owing to the growing prevalence of chronic diseases and the presence of highly advanced medical infrastructure
In Asia Pacific, the market is anticipated to witness significant growth over the forecast period owing to improving healthcare systems, rising healthcare expenditure, and growing awareness
Grand View Research has divided the global high pressure contrast media injector market report into segments according to product, type, application, end use, and region:
High Pressure Contrast Media Injectors Product Outlook (Revenue, USD Million, 2018 - 2030)
Injector Systems
Consumables
Syringes
Tubing
Others
High Pressure Contrast Media Injectors Type Outlook (Revenue, USD Million, 2018 - 2030)
Single Head Injectors
Dual Head Injectors
Syringeless Injectors
High Pressure Contrast Media Injectors Application Outlook (Revenue, USD Million, 2018 - 2030)
Interventional Cardiology
Interventional Radiology
Endovascular Surgery
Interventional Neuroradiology
High Pressure Contrast Media Injectors End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic Centers
Ambulatory Surgical Centers
High Pressure Contrast Media Injectors Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Switzerland
Belgium
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
List of Key Players in High Pressure Contrast Media Injectors Market
Bracco Group
Guerbet Group
MEDTRON AG
Bayer Healthcare LLC
Ulrich GmbH & Co. Kg
Nemotokyorindo Co., Ltd
GE Healthcare
Sino Medical-Device Technology Co.
Apollo RT Co. Ltd.
VIVID Imaging
"The quality of research they have done for us has been excellent..."